e-learning
resources
London 2016
Wednesday, 07.09.2016
Lung cancer: therapeutic modalities, re-staging, and follow-up
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival
Hela Cherif (Tunis, Tunisia), Hela Cherif, Saoussen Bacha, Sonia Habibech, Hager Racil, Sana Cheikhrouhou, Naouel Chaouech, Abdellatif Chabbou, Mohamed Lamine Megdiche
Source:
International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Session:
Lung cancer: therapeutic modalities, re-staging, and follow-up
Session type:
Poster Discussion
Number:
4841
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hela Cherif (Tunis, Tunisia), Hela Cherif, Saoussen Bacha, Sonia Habibech, Hager Racil, Sana Cheikhrouhou, Naouel Chaouech, Abdellatif Chabbou, Mohamed Lamine Megdiche. Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival. Eur Respir J 2016; 48: Suppl. 60, 4841
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Anticancer treatment for advanced non-small cell lung cancer
Source: Breathe 2011; 8: 124-133
Year: 2011
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Source: ERS webinar 2021: Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Year: 2021
Radiotherapy in the treatment of nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 207–243
Year: 2009
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Combined radiotherapy for nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy?
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Radiotherapy with curative intent for stage I and II non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Chemotherapy in nonsmall cell lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=218
Year: 2001
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008
Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer?
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept